Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Healthy right-handed volunteers aged 21 to 50 needed for a research study of the effects of morphine and ketorolac on brain activity in response to pain stimuli as measured by functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET). Study will be conducted on six separate days not requiring an overnight stay in the hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Morphine condition | Experimental |
| |
| Ketorolac condition | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Integrated MR-PET scan | Radiation | Integrated MR-PET scan using [11C]diprenorphine |
|
| Measure | Description | Time Frame |
|---|---|---|
| fMRI Signal Changes | Obtain information about brain activity, including BOLD (Blood-oxygen-level dependent) signal, using an fMRI system. Data analysis was applied using SPM 12 with a standard pipeline. | one day |
| Pain Ratings | The primary endpoint was the morphine and ketorolac conditioning effects as indicated by subjective pain rating changes between pain only (a control condition with no injection of glucose, but subject's did see an image of an hour glass displaying how much time they had before receiving a painful stimulus) and pain+glucose (subjects received a glucose injection accompanied by an injection schematic followed by a painful stimulus) within the morphine and ketorolac groups. We used the Gracely pain rating scale (ranging from 0, no sensation to 20, extremely painful). | One day |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Current or past history of major medical, neurological, or psychiatric illness
Women who are pregnant or breast feeding, have gone through menopause, or have irregular menstrual cycles (length of cycle must be within 26 to 32 days)
Contraindications to morphine administration:
Contraindications to ketorolac administration
Contraindications to fMRI scanning (including cardiac pacemaker, metal implants, claustrophobia, pregnancy)
Contraindications to either of the emergency medications (Ondansetron or Narcan)
History of head trauma
High blood pressure (>140 systolic, >90 diastolic)
History of impaired urinary elimination
Major kidney problems, bleeding problems, severe dehydration, or recovering from a recent surgery (within past year).
Instability of responses to experimental pain (see Study Procedures Section)
History of asthma
History of diabetes
Liver Function Test results greater than 2.5 times the upper limit of normal (ULN) at Screening
History of smoking (past or current)
Use of psychotropic drugs, hormone treatments (including hormonal birth control) within 1 year
Non-fluent speaker of English
Positive urine drug screen (i.e. positive on any of the 10 measures tested, including cocaine, marijuana, opiates, amphetamines, methamphetamines, phencyclidine, barbiturates, benzodiazepines, methadone, and tricyclic antidepressants)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Charlestown | Massachusetts | 02129 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Morphine Condition | Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine Morphine: 3 administrations of morphine over course of study |
| FG001 | Ketorolac Condition | Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine Ketorolac: 3 administrations of ketorolac over course of study |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Morphine Condition | Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine Morphine: 3 administrations of morphine over course of study |
| BG001 | Ketorolac Condition |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | fMRI Signal Changes | Obtain information about brain activity, including BOLD (Blood-oxygen-level dependent) signal, using an fMRI system. Data analysis was applied using SPM 12 with a standard pipeline. | Here we present the average fMRI (functional MRI) signal changes of clusters that survived a threshold of 0.005 with10 continuous voxels. We only reported beta values in pain related areas. | Posted | Mean | Standard Deviation | Beta value | one day |
|
Adverse event data was collected for each participant over a 3 hours period (from time of drug administration until they left 3 hours later). We collected this for every participant throughout our study.
Our definitions are consistent. After every drug administration we asked a standard questionnaire, which we also asked again a couple of hours following the initial drug administration. Specifically, we asked subjects if they felt nauseous, indigestion, itching, spacey/drugged, lightheadedness/faint, sense of difficulty concentrating, or sleepy.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Morphine Condition | Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine Morphine: 3 administrations of morphine over course of study |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Drug related reactions | Surgical and medical procedures | Non-systematic Assessment | Drug related reactions to morphine and ketorolac, including feeling nauseous, spacey, and drugged. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Jian Kong | Massachusetts General Hospital | 617-726-7893 | jkong2@mgh.harvard.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 15, 2016 | Feb 8, 2018 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D020910 | Ketorolac |
| ID | Term |
|---|---|
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ketorolac | Drug | 3 administrations of ketorolac over course of study |
|
Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Ketorolac: 3 administrations of ketorolac over course of study
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Pain Ratings | Some subjects were dropped before or during the MRI scan in which baseline pain ratings were collected. We used the Gracely Sensory Pain Scale (0-20; 0: no pain, 20: intolerable pain) to rate the pain subject's experienced. | Mean | Standard Deviation | scores on a scale |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Pain Ratings | The primary endpoint was the morphine and ketorolac conditioning effects as indicated by subjective pain rating changes between pain only (a control condition with no injection of glucose, but subject's did see an image of an hour glass displaying how much time they had before receiving a painful stimulus) and pain+glucose (subjects received a glucose injection accompanied by an injection schematic followed by a painful stimulus) within the morphine and ketorolac groups. We used the Gracely pain rating scale (ranging from 0, no sensation to 20, extremely painful). | Posted | Mean | Standard Deviation | units on a scale | One day |
|
|
|
| 0 |
| 22 |
| 0 |
| 22 |
| 5 |
| 22 |
| EG001 | Ketorolac Condition | Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine Ketorolac: 3 administrations of ketorolac over course of study | 0 | 29 | 0 | 29 | 1 | 29 |
|
Not provided
Not provided
| D006571 | Heterocyclic Compounds |
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|